SCHEMBL25192576

SCHEMBL25192576

CCN(Cc1cc([N+](=O)[O-])cc(Cl)c1O)C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.48
HTT P42858 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GALR3 O60755 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 4/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.38
VCAM1 P19320 1/20 0.37
NR1H4 Q96RI1 1/20 0.36
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
HSD17B10 Q99714 1/20 0.35
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25190069 0.83 GPR35 (0.53) GPR35HTTMEN1KMT2AGALR3
SCHEMBL9452233 0.81 GPR35 (0.61) GPR35HTTMEN1KMT2AGALR3
SCHEMBL25190368 0.81 CDC25C (0.46) GPR35HTTSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL25199860 0.80 GPR35 (0.47) GPR35HTTMEN1KMT2AGALR3
SCHEMBL25190113 0.78 GPR35 (0.48) GPR35HTTMEN1KMT2AALDH1A1
SCHEMBL25188801 0.78 GPR35 (0.50) GPR35HTTMEN1KMT2AGALR3
SCHEMBL25183606 0.77 GPR35 (0.47) GPR35HTTMEN1KMT2AGALR3
SCHEMBL27979430 0.77 GPR35 (0.56) GPR35HTTMEN1KMT2AGALR3
SCHEMBL25200927 0.76 GPR35 (0.46) GPR35HTTMEN1KMT2AGALR3
SCHEMBL25190096 0.76 GPR35 (0.46) GPR35HTTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325547-A1 ANTI-SARS-COV-2 DRUG KAGOSHIMA UNIVERSITY (JP) 2025-10-23 US disclosed
EP-4431151-A1 ANTI-SARS-COV-2 DRUG Kagoshima University (JP) 2024-09-18 EP disclosed
CN-118302413-A Anti-SARS-CoV-2 medicine 国立大学法人鹿儿岛大学 2024-07-05 CN disclosed
WO-2023085392-A1 ANTI-SARS-COV-2 DRUG 国立大学法人鹿児島大学 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325547-A1 ANTI-SARS-COV-2 DRUG ACE2, ACE, AGTR2 GPR35 1908/4885HTT 1537/4885MEN1 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.